Assessment of Elderly Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
ELDERGRAF
Multi-domain Assessment and Quality of Life in Patients Older Than 60 Years Receiving an Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
1 other identifier
observational
205
1 country
18
Brief Summary
Patients older than 60 years are more and more transplanted. Comprehensive geriatric assessment (CGA) have been developed and are currently used in patients with cancer, it has been correlated with the prognosis. There is still few data in transplanted patients and the aim of this study is to assess these patients before and after transplantation in order to monitor their general health and quality of life (QOF) and correlate them to the prognostic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2020
Longer than P75 for all trials
18 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 28, 2020
CompletedFirst Posted
Study publicly available on registry
May 5, 2020
CompletedStudy Start
First participant enrolled
July 3, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 17, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 17, 2024
CompletedJune 26, 2024
June 1, 2024
3.3 years
April 28, 2020
June 24, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Overall survival
at one year post allogeneic hematopoietic stem cell transplantation
Secondary Outcomes (27)
Overall survival
at two years post allogeneic hematopoietic stem cell transplantation
Morbidity Index
at one year
Morbidity Index
at two years
Survival without disease and chronic graft-versus-host disease
at one year post allogeneic hematopoietic stem cell transplantation
Survival without disease and chronic graft-versus-host disease
at two years post allogeneic hematopoietic stem cell transplantation
- +22 more secondary outcomes
Interventions
Questionnaires on nutritional status, autonomy and quality of life
Eligibility Criteria
Patients over 60 years who received an allogeneic hematopoietic stem cell transplantation HSCT
You may qualify if:
- years or more at time of transplantation
- Patient receiving a hematopoietic stem cell allograft for myeloid hemopathy (myeloid acute leukemia, myelodysplastic syndrome, Myeloproliferative neoplasm) or for an Acute lymphoblastic leukemia
- No opposition to participate
You may not qualify if:
- Patient opposed to the protocol
- Vulnerable patients protected by curatorship or administrative supervision
- Patients not covered by a social security scheme
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (18)
CHU Amiens
Amiens, France
CHU Angers
Angers, France
CHU Besancon
Besançon, France
CHU Bordeaux
Bordeaux, France
CHU Caen
Caen, France
CHU Clermont-Ferrand
Clermont-Ferrand, France
CHU Grenoble
Grenoble, France
CHRU Lille
Lille, France
CHU Limoges
Limoges, France
CHU Lyon
Lyon, France
CHU Montpellier
Montpellier, France
CHRU Nancy
Nancy, France
CHU Nantes
Nantes, France
CHU Nice
Nice, France
Hopital de la Pitié Salpetrière
Paris, France
Hopital Necker
Paris, France
Hopital Saint Louis
Paris, France
CHU Toulouse
Toulouse, France
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 28, 2020
First Posted
May 5, 2020
Study Start
July 3, 2020
Primary Completion
October 17, 2023
Study Completion
October 17, 2024
Last Updated
June 26, 2024
Record last verified: 2024-06